All governance proposals passed as expected — no surprises. The authorized share increase could facilitate future dilutive financing, but no such offering was announced. Monitor for any subsequent capital raise given the company's going concern status noted in the prior 20-F.
Price Chart
Executive Summary
Scinai Immunotherapeutics filed an 8-K reporting results of its June 16, 2026 Annual Meeting of Shareholders. All eight proposals passed with strong shareholder support, including re-election of directors, an increase in authorized ordinary shares, executive compensation amendments, and ratification of auditors. The filing is a routine post-meeting disclosure with no material financial or operational new information.
Key Facts
- Shareholders approved an amendment to increase the number of authorized ordinary shares (Proposal 3).
- Shareholders approved re-election of directors Sam Moed, Yael Margolin, and Adi Raviv.
- Shareholders approved amended employment agreement and RSU grant for CEO Amir Reichman.
- Shareholders approved extension of Chairman Mark Germain's service agreement and a special RSU grant for him.
- Zvi Haft / BDO ratified as auditors for 2026.
- Total shares entitled to vote: 15,839,168,000 ordinary shares (3,959,792 ADSs). Quorum present.
Financial Impact
No financial figures disclosed. Authorized share increase enables future equity issuances but no actual offering was announced.
Risk Factors
- Authorized share increase creates capacity for future dilutive offering.
- Company remains under going concern risk and Nasdaq delisting threat per prior 20-F filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-069407 |
| Document: 0001213900-26-069407-index-headers.html | 0001213900-26-069407 |
| Document: 0001213900-26-069407-index.html | 0001213900-26-069407 |
| Document: 0001213900-26-069407.txt | 0001213900-26-069407 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 6-K | $0.6813 | awaiting T+60 | — | $0.5562 (−18.36%) |
Oct 16, 2026 10d ago | 6-K | $0.7520 | awaiting T+60 | — | $0.5562 (+26.04%) |
Oct 16, 2026 11d ago | Press Release | $0.7524 | awaiting T+60 | — | $0.5562 (+26.08%) |
Oct 15, 2026 12d ago | 6-K | $0.9015 | awaiting T+60 | — | $0.5562 (+38.30%) |
Oct 13, 2026 14d ago | 6-K | $1.23 | awaiting T+60 | — | $0.5562 (−54.78%) |
Oct 6, 2026 21d ago | EFFECT | $1.22 | awaiting T+60 | — | $0.5562 (+54.41%) |
Sep 21, 2026 5w ago | 6-K | $1.69 | awaiting T+60 | — | $0.5562 (−67.09%) |
Aug 26, 2026 8w ago | 6-K | $2.87 | awaiting T+60 | — | $0.5562 (+80.62%) |
Aug 19, 2026 9w ago | 6-K | $0.2740 | awaiting T+60 | — | $0.5562 (−102.99%) |
Jun 17, 2026 18w ago | 6-K | $0.3370 $0.2440 | ▼ −27.60% | ▼ −30.28% | $0.5562 (+65.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers